EGFR-TKIs

DRUG2 trials

Sponsors

Nagasaki Thoracic Oncology Group, Xinqiao Hospital of Chongqing

Conditions

NSCLCNon Small Cell Lung Cancer

Phase 2

Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC

TerminatedNCT02353741

Xinqiao Hospital of ChongqingNon Small Cell Lung Cancer

Start: 2015-04-30End: 2018-12-01Updated: 2018-12-21

Unknown Phase

To evaluate the relationships between the serum concentration of EGFR-TKIs and the effects and toxicities of them

Active, not recruitingJPRN-UMIN000001066

Nagasaki Thoracic Oncology GroupNSCLC

Start: 2007-02-01Target: 50Updated: 2026-06-29

Related Papers

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.

2016-06-2311 citations